{"id":"hum0209","version":1,"url":"https://humandbs.dbcls.jp/research/hum0209/v1","datePublished":"2019-12-13","versions":[{"version":1,"datePublished":"2019-12-13"}],"title":{"ja":"関節リウマチ治療におけるメトトレキサートの効果と副作用予測のための多施設研究","en":"Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study"},"summary":{"aims":{"ja":"関節リウマチ（rheumatoid arthritis：RA）患者におけるメトトレキサート（methotrexate：MTX）の治療効果と副作用に関連する変異を予測因子として構築した予測モデルの評価","en":"To develop genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA)."},"methods":{"ja":"MTXで加療されたRA患者を対象にDrug Metabolizing Enzymes and Transporters Array（DMET）およびダイレクトシークエンス法により1966のgenotypeを決定し、集積する。有効性はEULAR反応性指標を用い、肝機能障害は正常値の1.5倍以上と定義する。genotypeおよび臨床情報によりMTX治療の有効性および肝機能障害の予測モデルを構築する。","en":"Among RA patients treated with MTX, 1,966 polymorphisms of 246 enzymes/transporters relevant to pharmacokinetics and pharmacodynamics were detected by the Drug Metabolism Enzymes and Transporters (DMET) microarray and direct sequencing, and clinical variables at baseline were collected. For efficacy, response criteria of the European League Against Rheumatism were used to classify patients as responders or non-responders. Hepatotoxicity was defined as elevations of aspartate aminotransferase or alanine aminotransferase equal to or greater than 1.5 times the reference range upper limit. Genetic and clinical prediction models for the efficacy and hepatotoxicity of MTX were developed in patients with RA."},"targets":{"ja":"MTXで加療されたRA166症例","en":"166 RA patients"},"url":{"ja":null,"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"関節リウマチ：166症例\n（日本人）","en":"Rheumatoid arthritis: 166 cases\n(Japanese)"},"typeOfData":{"ja":"SNP-chip\nダイレクトシークエンス","en":"SNP-chip\nDirect sequencing"}},"releaseNote":{"ja":"メトトレキサート（MTX）治療を受けた関節リウマチ（RA）166症例の末梢血から抽出したDNAを対象とし、Drug Metabolizing Enzymes and Transporters Array（DMET；Affymetrix）およびダイレクトシークエンス法により遺伝子型決定をした変異のGenotype頻度情報をcsv形式にて提供する。","en":"DNAs extracted from peripheral blood cells of rheumatoid arthritis (RA) patients treated with methotrexate (MTX) were genotyped by the Drug Metabolizing Enzymes and Transporters (DMET) Array (Affymetrix) and direct sequencing. Genotype frequencies are provided (csv files)."},"dataProviders":[{"name":{"ja":"熊谷 俊一","en":"Shunichi Kumagai"},"organization":{"name":{"ja":"神鋼記念病院 診療部 膠原病リウマチセンター","en":"Center for Rheumatic Diseases, Shinko Hospital"}}}],"researchProjects":[],"grants":[],"relatedPublications":[{"title":"Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study","doi":"https://doi.org/10.1038/s41397-019-0134-9","datasets":["NHA000130"]}],"datasets":["NHA000130"],"controlledAccessUsers":[]}